Effects of the CRF1 receptor antagonist SSR125543 on energy balance and food deprivation-induced neuronal activation in obese Zucker rats

Journal of Endocrinology

Volumn 193, Issue 1, 2007, Pages 11-19

  Doyon, Christian ^a,b   Samson, Pierre ^a   Lalonde, Josée ^a   Richard, Denis ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; FAT; GLUCOSE; LEPTIN; MESSENGER RNA; PROTEIN C FOS; TRIACYLGLYCEROL; UNCOUPLING PROTEIN 1; CORTICOTROPIN RELEASING FACTOR; CRF RECEPTOR TYPE 1; FATTY ACID; HALOGENATED HYDROCARBON; INSULIN; PROTEIN; THIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARCUATE NUCLEUS; ARTICLE; CARCASS; CELL ACTIVATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DIABETES MELLITUS; DIET RESTRICTION; ENERGY BALANCE; FOOD DEPRIVATION; HOMEOSTASIS; HORMONE RESPONSE; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LEAN BODY WEIGHT; MALE; METABOLIC SYNDROME X; NERVE CELL; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; STRESS; THALAMUS MIDLINE NUCLEUS; ZUCKER RAT; ANIMAL; BLOOD; DRUG ANTAGONISM; ENERGY METABOLISM; GENE EXPRESSION; GENETICS; GLUCOSE BLOOD LEVEL; HYPOTHALAMUS; IN SITU HYBRIDIZATION; METABOLISM; METHODOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BLOOD GLUCOSE; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; FOOD DEPRIVATION; GENE EXPRESSION; HYDROCARBONS, HALOGENATED; HYPOTHALAMUS; IN SITU HYBRIDIZATION; INSULIN; INSULIN RESISTANCE; MALE; OBESITY; PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, ZUCKER; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZINES; TRIGLYCERIDES;

EID: 34247403484     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.07064     Document Type: Article

References (56)

1. Arase K, York DA, Shimizu H, Shargill N & Bray GA 1988 Effects of corticotropin-releasing factor on food intake and brown adipose tissue thermogenesis in rats. American Journal of Physiology 255 E255-E259.
2. Arborelius L, Skelton KH, Thrivikraman KV, Plotsky PM, Schulz DW & Owens MJ 2000 Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. Journal of Pharmacology and Experimental Therapeutics 294 588-597.
3. Arvaniti K, Ricquier D, Champigny O & Richard D 1998 Leptin and corticosterone have opposite effects on food intake and the expression of UCP1 mRNA in brown adipose tissue of lepob/lepob mice. Endocrinology 139 4000-4003.
4. Arvaniti K, Huang Q & Richard D 2001 Effects of leptin and corticosterone on the expression of corticotropin-releasing hormone, agouti-related protein, and proopiomelanocortin in the brain of ob/ob mouse. Neuroendocrinology 73 227-236.
5. Bornstein SR, Webster EL, Torpy DJ, Richman SJ, Mitsiades N, Igel M, Lewis DB, Rice KC, Joost HG, Tsokos M et al. 1998 Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology 139 1546-1555.
6. Brown MR, Fisher LA, Rivier J, Spiess J, Rivier C & Vale W 1982a Corticotropin-releasing factor: effects on the sympathetic nervous system and oxygen consumption. Life Sciences 30 207-210.
7. Brown MR, Fisher LA, Spiess J, Rivier C, Rivier J & Vale W 1982b Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism. Endocrinology 111 928-931.
8. Castonguay TW, Dallman MF & Stern JS 1986 Some metabolic and behavioral effects of adrenalectomy on obese Zucker rats. American Journal of Physiology 251 R923-R933.
9. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL et al. 1996 Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine 334 292-295.
10. Currie PJ, Coscina DV, Bishop C, Coiro CD, Koob GF, Rivier J & Vale W 2001 Hypothalamic paraventricular nucleus injections of urocortin alter food intake and respiratory quotient. Brain Research 916 222-228.
11. De Fanti BA & Martínez JA 2002 Central urocortin activation of sympathetic-regulated energy metabolism in Wistar rats. Brain Research 930 37-41.
12. Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, Maier SF, Licinio J, Wong ML, Chrousos GP, Webster E et al. 1999 The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140 79-86.
13. Doyon C, Moraru A & Richard D 2004 The corticotropin-releasing factor system as a potential target for antiobesity drugs. Drug News Perspectives 17 505-517.
14. Doyon C, Denis RG, Baraboi ED, Samson P, Lalonde J, Deshaies Y & Richard D 2006 Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 55 3403-3410.
15. Feldkircher KM, Mistry AM & Romsos DR 1996 Adrenalectomy reverses pre-existing obesity in adult genetically obese (ob/ob) mice. International Journal of Obesity and Related Metabolic Disorders 20 232-235.
16. Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB & Flier JS 1995 Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nature Medicine 1 1311-1314.
17. Freedman MR, Horwitz BA & Stern JS 1986 Effect of adrenalectomy and glucocorticoid replacement on development of obesity. American Journal of Physiology 250 R595-R607.
18. Galpin KS, Henderson RG, James WP & Trayhurn P 1983 GDP binding to brown-adipose-tissue mitochondria of mice treated chronically with corticosterone. Biochemical Journal 214 265-268.
19. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP & Soubrié P 2002 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-l- (3-fluoro-4-methylpheny-1)ethyl]5-methyl-N- (2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor1 receptor antagonist. II. Characterization in rodent models of stress-related disorders. Journal of Pharmacology and Experimental Therapeutic 301 333-345.
20. Guillaume-Gentil C, Rohner-Jeanrenaud F, Abramo F, Bestetti GE, Rossi GL & Jeanrenaud B 1990 Abnormal regulation of the hypothalamo-pituitary-adrenal axis in the genetically obese fa/fa rat. Endocrinology 126 1873-1879.
21. Gully D, Geslin M, Serva L, Fontaine E, Roger P, Lair C, Darre V, Marcy C, Rouby PE, Simiand J et al. 2002 4-(2-Chloro-4-methoxy-5-methylphenyl)- N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5- methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor1 receptor antagonist. Journal of Pharmacology and Experimental Therapeautics 301 322-332.
22. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C et al. 2000 Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. PNAS 97 6079-6084.
23. Hardwick AJ, Linton EA & Rothwell NJ 1989 Thermogenic effects of the antiglucocorticoid RU-486 in the rat: involvement of corticotropin-releasing factor and sympathetic activation of brown adipose tissue. Endocrinology 124 1684-1688.
24. Hasselgren PO 1999 Glucocorticoids and muscle catabolism. Current Opinion in Clinical Nutrition and Metabolic Care 2 201-205.
25. Heinrichs SC & Richard D 1999 The role of corticotropin-releasing factor and urocortin in the modulation of ingestive behavior. Neuropeptides 33 350-359.
26. Herman JP, Schafer MK, Thompson RC & Watson SJ 1992 Rapid regulation of corticotropin-releasing hormone gene transcription in vivo. Molecular Endocrinology 6 1061-1069.
27. Hotta M, Shibasaki T, Arai K & Demura H 1999 Corticotropin-releasing factor receptor type 1 mediates emotional stress-induced inhibition of food intake and behavioral changes in rats. Brain Research 823 221-225.
28. Imaki T, Shibasaki T, Hotta M & Demura H 1992 Early induction of c-fos precedes increased expression of corticotropin-releasing factor messenger ribonucleic acid in the paraventricular nucleus after immobilization stress. Endocrinology 131 240-246.
29. Jingami H, Matsukura S, Numa S & Imura H 1985 Effects of adrenalectomy and dexamethasone administration on the level of prepro-corticotropin-releasing factor messenger ribonucleic acid (mRNA) in the hypothalamus and adrenocorticotropin/beta-lipotropin precursor mRNA in the pituitary in rats. Endocrinology 117 1314-1320.
30. Johnson PR, Greenwood MR, Horwitz BA & Stern JS 1991 Animal models of obesity: genetic aspects. Annual Review of Nutrition 11 325-353.
31. Kolaczynski JW, Ohannesian JP, Considine RV, Marco CC & Caro JF 1996 Response of leptin to short-term and prolonged overfeeding in humans. Journal of Clinical Endocrinology and Metabolism 81 4162-4165.
32. LeFeuvre RA, Rothwell NJ & Stock MJ 1987 Activation of brown fat thermogenesis in response to central injection of corticotropin releasing hormone in the rat. Neuropharmacology 26 1217-1221.
33. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S et al. 1995 Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Medicine 1 1155-1161.
34. Marchington D, Rothwell NJ, Stock MJ & York DA 1983 Energy balance, diet-induced thermogenesis and brown adipose tissue in lean and obese (fa/fa) Zucker rats after adrenalectomy. Journal of Nutrition 113 1395-1402.
35. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 412-419.
36. Ohata H, Arai K & Shibasaki T 2002 Effect of chronic administration of a CRF1 receptor antagonist, CRA1000, on locomotor activity and endocrine responses to stress. European Journal of Pharmacology 457 201-206.
37. Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A, Kumagai T, Okubo T & Tomisawa K 1999 Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. Journal of Pharmacology and Experimental Therapeutics 289 926-935.
38. Pelleymounter MA, Joppa M, Carmouche M, Cullen MJ, Brown B, Murphy B, Grigoriadis DE, Ling N & Foster AC 2000 Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. Journal of Pharmacology and Experimental Therapeutics 293 799-806.
39. Richard D, Rivest R, Naïmi N, Timofeeva E & Rivest S 1996 Expression of corticotropin-releasing factor and its receptors in the brain of lean and obese Zucker rats. Endocrinology 137 4786-4795.
40. Richard D, Lin Q & Timofeeva E 2002 The corticotropin-releasing factor family of peptides and CRF receptors: their roles in the regulation of energy balance. European Journal of Pharmacology 440 189-197.
41. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T et al. 1996 CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. PNAS 93 10477-10482.
42. Sell H, Deshaies Y & Richard D 2004 The brown adipocyte: update on its metabolic role. International Journal of Biochemistry and Cell Biology 36 2098-2104.
43. Simmons DM, Arriza JL & Swanson LW 1989 A complete protocol for in situ hybridization of messenger RNAs in brain and other tissues with radiolabeled single-stranded RNA probes. Journal of Histotechnology 12 169-181.
44. Smagin GN, Howell LA, Ryan DH, De Souza EB & Harris RB 1998 The role of CRF2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia. Neuroreport 9 1601-1606.
45. Strack AM, Bradbury MJ & Dallman MF 1995 Corticosterone decreases nonshivering thermogenesis and increases lipid storage in brown adipose tissue. American Journal of Physiology 268 R183-R191.
46. Takahashi LK 2001 Role of CRF1 and CRF2 receptors in fear and anxiety. Neuroscience and Biobehavioral Reviews 25 627-636.
47. Timofeeva E & Richard D 1997 Functional activation of CRH neurons and expression of the genes encoding CRH and its receptors in food-deprived lean (Fa/?) and obese (fa/fa) Zucker rats Neuroendocrinology 66 327-340.
48. Timofeeva E & Richard D 2001 Activation of the central nervous system in obese Zucker rats during food deprivation. Journal of Comparative Neurology 441 71-89.
49. Triscari J, Stern JS, Johnson PR & Sullivan AC 1979 Carbohydrate metabolism in lean and obese Zucker rats. Metabolism 28 183-189.
50. Webster AJF 1983 Energetics of maintenance and growth. In Mammalian Thermogenesis, pp 178-207. Eds L Girardier & M Stock. London: Chapman & Hall.
51. Wong ML, Webster EL, Spokes H, Phu P, Ehrhart-Bornstein M, Bornstein S, Park CS, Rice KC, Chrousos GP, Licinio J et al. 1999 Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sciences 65 PL53-PL58.
52. Young WS 3rd, Mezey E & Siegel RE 1986 Quantitative in situ hybridization histochemistry reveals increased levels of corticotropin-releasing factor mRNA after adrenalectomy in rats. Neuroscience Letters 70 198-203.
53. Yukimura Y & Bray GA 1978 Effects of adrenalectomy on body weight and the size and number of fat cells in the Zucker (fatty) rat. Endocrine Research Communications 5 189-198.
54. Yukimura Y, Bray GA & Wolfsen AR 1978 Some effects of adrenalectomy in the fatty rat. Endocrinology 103 1924-1928.
55. Zorrilla EP, Valdez GR, Nozulak J, Koob GF & Markou A 2002 Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Research 952 188-199.
56. Zucker LM & Antoniades HN 1972 Insulin and obesity in the Zucker genetically obese rat 'fatty'. Endocrinology 90 1320-1330.